Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A validated gene regulatory network and GWAS identifies early regulators of T cell-associated diseases.
Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence.
Avonex approval application
A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE)
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Cuprizone neurotoxicity in the rat: morphologic observations.
Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination.
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β.
Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication.
Delta-9-tetrahydrocannabinol/cannabidiol (sativex(®)): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis.
Microglia across the lifespan: from origin to function in brain development, plasticity and cognition.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
“Human Medicines” page
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Rituximab does not reset defective early B cell tolerance checkpoints.
Autoantibodies and pain.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.

Pages